U Maryland-Baltimore licenses lung injury treatment to GEn1E Lifesciences
Published 10/24/18 on Tech Transfer eNews Blog Preclinical stage drug developer GEn1E Lifesciences has entered into a license agreement with the University of Maryland-Baltimore (UMB) to commercialize a treatment for acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Developed by UMB …